NCT05429450View on ClinicalTrials.gov

Thyroid Associated Orbitopathy Treatment by Methotrexate Against Triamcinolone Periocular Injections

PHASE2CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

July 1, 2020

Primary Completion Date

July 1, 2022

Study Completion Date

July 15, 2022

Conditions
Thyroid Associated Orbitopathy
Interventions
DRUG

Methotrexate

Three periocular injections of methotrexate at week 0, week 3 and week 6.

DRUG

Triamcinolone Acetonide

Three periocular injections of triamcinolone acetonide at week 0, week 3 and week 6.

Trial Locations (1)

Unknown

Cairo University, Cairo

All Listed Sponsors
lead

Cairo University

OTHER

NCT05429450 - Thyroid Associated Orbitopathy Treatment by Methotrexate Against Triamcinolone Periocular Injections | Biotech Hunter | Biotech Hunter